Pipeline

We use our proprietary platform technology to create nucleic acid drugs that are optimized for the treatment of diseases.

PURMX's solution is to fine-tune a large number of target genes to create small RNA nucleic acid drugs with unprecedented therapeutic efficacy.

PURMX already possesses a large amount of functional RNA screening data, which is being further expanded.

The first stage of innovative nucleic acid medicine seeds is MIRX002.

MIRX002 seeds have already completed non-clinical trials and are being tested in Japan for malignant pleural mesothelioma from 2021 in an investigator-initiated clinical trial.

Global clinical trials for malignant pleural mesothelioma and head and neck cancer are planned to be conducted in the U.S., Australia, and Japan from 2024.